研究晚期非小细胞肺癌(non-small cell lung cancer, NSCLC)表皮生长因子受体(epidermal growth factor receptor, EGFR)基因突变情况和该基因突变状态对吉非替尼疗效的影响。. This evidence concerns the gene EGFR and non-small cell lung carcinoma.